Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
VANCOUVER, British Columbia, Dec. 12, 2024 (GLOBE NEWSWIRE) -- ANORTECH INC. (“AnorTech” or the “Company”) (TSX Venture Exchange “ANOR”; OTC “HUDRF”) is pleased to announce that it has received...
VANCOUVER, British Columbia, Sept. 06, 2024 (GLOBE NEWSWIRE) -- ANORTECH INC. (“AnorTech” or the “Company”) (TSX Venture Exchange “ANOR”; OTC “HUDRF”) has granted incentive stock options under...
VANCOUVER, British Columbia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- ANORTECH INC. (“AnorTech” or the “Company”) (TSX Venture Exchange “ANOR”; OTC “HUDRF”) is pleased to announce that it has completed...
Acquisition to Strengthen Transplant and Oncology Businesses CAMBRIDGE, Mass. and VANCOUVER, B.C., Nov. 7 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) and AnorMED Inc. (Nasdaq:...
CAMBRIDGE, Mass. and VANCOUVER, B.C., Nov. 7 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) and AnorMED Inc. (Nasdaq: ANOR; TSX: AOM) announced today the expiration of the waiting...
AnorMED Board Recommends Shareholders Accept Genzyme Offer LANGLEY, BC, Nov. 3 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or the "Company") (NASDAQ:ANOR; TSX:AOM) today released its...
VANCOUVER, Oct. 23 /PRNewswire-FirstCall/ -- AnorMED Inc. (NASDAQ:ANOR; TSX:AOM) today announced that it has completed enrollment in the second pivotal Phase III clinical trial evaluating its...
Genzyme to Gain Late-Stage Transplantation Product Candidate VANCOUVER, BC, and CAMBRIDGE, MA, Oct. 17 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) and AnorMED Inc. (Nasdaq: ANOR;...
Millennium has the right to match Genzyme's 'superior proposal' VANCOUVER, Oct. 11 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or "the Company") (NASDAQ:ANOR; TSX:AOM) announced that it...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.01 | -33.3333333333 | 0.03 | 0.03 | 0.02 | 256066 | 0.025 | CS |
| 4 | -0.005 | -20 | 0.025 | 0.03 | 0.02 | 143340 | 0.02558076 | CS |
| 12 | -0.005 | -20 | 0.025 | 0.03 | 0.015 | 115584 | 0.02236118 | CS |
| 26 | 0 | 0 | 0.02 | 0.035 | 0.015 | 94263 | 0.02426573 | CS |
| 52 | -0.01 | -33.3333333333 | 0.03 | 0.05 | 0.015 | 81704 | 0.02568442 | CS |
| 156 | -0.01 | -33.3333333333 | 0.03 | 0.05 | 0.015 | 81704 | 0.02568442 | CS |
| 260 | -0.01 | -33.3333333333 | 0.03 | 0.05 | 0.015 | 81704 | 0.02568442 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
